Substituted fused pyrimidine compounds

US8859566B2 · kind B2 · utility

Assignee

• Advinus Therapeutics Limited

Inventors

• Venkata P. Palle · Mountain View, US
• Vidya Ramdas · Pune, IN
• Dinesh Barawkar · Lake Forest, US
• Sujay Basu · Mumbai, IN
• Summon Koul · Pimpri-Chinchwad, IN
• Yogesh Waman · Pune, IN
• Meena Patel · Libertyville, US
• Anil Panmand · Pimpri-Chinchwad, IN

Key dates

• Filing date: Mar 12, 2010
• Grant date: Oct 14, 2014
• Expiry date: Apr 6, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D473/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention discloses substituted fused pyrimidine compounds of formula (I), their tautomers, polymorphs, stereoisomers, solvates, pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor, such as asthma, chronic obstructive pulmonary disorder, angiogenesis, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal tract disorders, and/or autoimmune diseases.